君实生物2025年一季度实现营收5.01亿元，同比增长31.46%，亏损持续收窄。核心产品特瑞普利单抗国内销售收入达4.47亿元，同比增长45.72%。公司研发投入3.51亿元，同比增长26.89%，推动多个管线进展，包括首个双抗ADC JS212进入临床。此外，民得维®在真实世界研究中显示出良好的安全性和疗效，尤其对老年和高风险患者效果显著。截至一季度末，君实生物拥有约30.22亿元的资金储备，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.